林业发展局批准Bimzelx在成人中治疗严重皮肤病、隐藏性脊髓灰质炎supppurativa。 FDA approves Bimzelx for treating severe skin condition hidradenitis suppurativa in adults.

林业发展局已核准Bimzelx(bimekizumab-bkzx)治疗成人中度至重度隐藏性炎(HS)。 The FDA has approved Bimzelx (bimekizumab-bkzx) for treating moderate to severe hidradenitis suppurativa (HS) in adults. HS是一种慢性发炎性皮肤疾病。 HS is a chronic inflammatory skin disease. Bimzelx是针对Interleukin 17A和17F的首种药物,表明临床试验中HS症状有显著改善。 Bimzelx is the first drug to target both interleukin 17A and 17F, showing significant improvements in HS symptoms in clinical trials. 这一批准标志着美国Bimzelx的第五个迹象,在此之前,美国对诸如关节炎和丙烯酰胺炎等病症进行了批准。 This approval marks the fifth indication for Bimzelx in the U.S., following earlier approvals for conditions such as psoriatic arthritis and ankylosing spondylitis.